Post-acquisition challenges in the wake of the Covid-19 pandemic in the pharmaceutical and biotech industry

Muriel Durand () and Maram Hassan
Additional contact information
Muriel Durand: Aarhus school of business - Aarhus School of Business, Métis Lab EM Normandie - EM Normandie - École de Management de Normandie = EM Normandie Business School

Post-Print from HAL

Abstract: This chapter examines global and virtual teamwork to determine how different practices may accelerate or hinder the post-deal integration process. We outline the challenges the pharmaceutical and biotechnology companies need to overcome in the virtual cross-border acquisitions. We then review a series of practical actions that may be employed to increase the probability of a successful virtual post-merger integration.

Date: 2024-04-05
References: Add references at CitEc
Citations:

Published in Routledge. Mergers and Acquisitions The Pharmaceutical and Biotechnology Industries, 2024, 9781003245438. ⟨10.4324/9781003245438⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-05423759

DOI: 10.4324/9781003245438

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().